Peptides for Alzheimer's: What the Research Shows
Alzheimer's disease remains one of medicine's hardest problems, and decades of amyloid-focused drug development have produced limited results. That has driven research interest in peptides that act on different targets — neurotrophic support, synapse formation, mitochondrial protection, and neuroinflammation. Here is an honest look at the compounds most often discussed, and how much evidence stands behind each.
Important. Alzheimer's is a serious progressive disease. None of these peptides is an approved treatment for it, and most evidence is preclinical. This article is educational only and is not a treatment plan. Decisions about Alzheimer's care must be made with a qualified neurologist.
Peptides Studied for Alzheimer's & Cognitive Decline
A mixture of low-molecular-weight neuropeptides derived from porcine brain. It mimics the action of endogenous neurotrophic factors, and is the most clinically studied compound on this list for Alzheimer's disease — with multiple randomised trials examining cognition and global function.
Evidence: Several randomised controlled trials in Alzheimer's; the strongest human dataset here
Cerebrolysin — Base PeptidesAn angiotensin IV analog reported to be orders of magnitude more potent than BDNF at promoting the formation of new synaptic connections in preclinical models. Research interest centres on its potential to rebuild connectivity lost in neurodegeneration.
Evidence: Preclinical only; striking animal data, no human trials
Dihexa — Base PeptidesA synthetic ACTH(4–10) fragment studied for cognition, focus, and neuroprotection. Research describes increases in BDNF and NGF expression and protection of neurons against ischaemic and oxidative stress — mechanisms relevant to age-related cognitive decline.
Evidence: Russian clinical use; extensive nootropic research, limited Alzheimer's-specific data
Semax — Base PeptidesA synthetic analog of the immunomodulatory peptide tuftsin. Beyond its anxiolytic effects, research describes modulation of BDNF and neuroinflammation — relevant to the mood and anxiety symptoms that frequently accompany cognitive decline.
Evidence: Clinical anxiolytic data; supportive rather than disease-modifying
Selank — Base PeptidesA peptide encoded in mitochondrial DNA with documented protective effects against amyloid-beta toxicity in laboratory models. It links mitochondrial health to neurodegeneration — a growing area of Alzheimer's research.
Evidence: Preclinical neuroprotection data; mechanistically compelling, early stage
Humanin — Base PeptidesA peptidergic compound studied for its ability to promote neurogenesis and reduce tau pathology in animal models of Alzheimer's disease, without the need for the parent neurotrophic protein.
Evidence: Preclinical animal models only
P21 — Base PeptidesThe compounds above act on genuinely different mechanisms. Cerebrolysin and Semax provide neurotrophic support; Dihexa and P21 target connectivity and neurogenesis; Humanin addresses mitochondrial resilience; Selank supports the mood and anxiety dimension. They are not interchangeable.
Only Cerebrolysin has a meaningful body of human trial data in Alzheimer's specifically. Everything else is preclinical or extrapolated from cognition research in healthy subjects — a crucial distinction the marketing rarely makes clear.
Neuroactive peptides demand especially careful sourcing — identity and purity directly affect both safety and any chance of a real effect. Insist on batch-specific third-party certificates of analysis.
If you are researching these for a family member with a diagnosis, involve their neurologist. Several of these compounds can interact with existing medications and care plans.
Other Articles
Calculator
Calculate exact reconstitution volumes and insulin unit doses for any peptide protocol.
Open Calculator →